On August 23rd, we produced the first in our new series of online Journal Clubs. Dr. med. Andreas Meister from the Kantonsspital Aarau presented the study “Rethinking Strategies for Stage III NSCLC” by Jeffrey Bradley, MD and discussed it with Dr. red. nat. Gerd Lutters, Dr. med. Jürg Heuberger and Prof. Niloy Datta form the Radiation Oncology Department of the Kantonsspital Aarau.
Many thanks to everybody involved and supportive of the project.
Recorded on August 23rd. Technical support: Michael Heuser. Production: Relatris.ch
With the financial support of AMGEN.
Another video from onclive.com, this time from the advanced prostate cancer series. The discussants talk about new treatment options, online since Friday July 12th. 2013.
As part of their Peer Exchange Series, onclive.com presents a discussion of the AGILE Trial by one of the collaborators, Thomas Hutson, and moderated by Daniel J. George from the Duke Cancer Institute in the Clinical Developments in Renal Cell Carcinoma section.
Published online July 22, 2013.
Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.
Published 10th of July 2013 by http://cancerGRACE.org/
One of the major topics at the ongoing World Congress on Gastrointestinal Cancers is personalized medicine (as it was at the ASCO 2013 Meeting). In the video below, Joseph Tabernero and Fortunato Ciardiello discuss personalized medicine in colorectal cancer. Video produced by ESMO channel.
justoncology, a blog by a medical oncologist, posted the first of three video sections of a peer exchange about The Advent of Cancer Immunotherapy. Find it at justoncology.wordpress.com and the second and third part at ajmc.com
In February 2013, the FDA approved T-DM1 (ado-trastuzumab emtansine; Kadcyla) for the treatment of patients with HER2-positive metastatic breast cancer. In this segment, panelists discuss the effectiveness of this agent and the pivotal EMILIA trial that led to its approval. Published June 24th 2013 by onclive.com
Dr. Mary Pinder reviews with Nathan Pennell and Howard West promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets. Video by cancergrace.org
On April 10th, 2013, our first “all-online” Journal Club was moderated by Dr. med. Richard Cathomas and joined by PD Dr. med. Frank Stenner and Dr. med. Philippe von Burg. The paper discussed was 2-weekly vs. 3-weekly docetaxel to treat castration-resistant prostate cancer: a randomised phase 3 trial by Kellokumpu-Lehtinen et al.; Lancet Oncology 2013;14:117-124 (abstract).
After a short introduction to the paper by Richard Cathomas, the participant discussed the value and the limitations of the finding that a 2-weekly administration of docetaxel leads to comparable results to a 3-weekly scheme, if a change of therapy will be implemented in their clinical work and if so, for which patients.
Please post questions or comments above (leave a reply) and we will refer them to the discussants.
The Journal Club on April 10th was the first one carried out completely online. It was a very valuable experience for everybody involved that will, as expected, lead to some immediate changes in the technical design.